Abstract:

The success of anti-amyloid-β (Aβ) monoclonal antibody has marked the beginning of the disease-modifying therapy (DMT) era for Alzheimer's disease (AD). As these agents are increasingly adopted in clinical practice, the focus of management has gradually shifted from standardized treatment initiation and amyloid-related imaging abnormalities (ARIA) management to long-term management after treatment discontinuation. Based on evidence from recent phase Ⅲ clinical trials, real-world studies, and clinical practice in China, this review summarizes the therapeutic benefits and current limitations of anti-Aβ monoclonal antibody and discusses its clinical value and ongoing challenges in the DMT era.

Key words: Alzheimer disease, Amyloid beta-peptides, Antibodies, monoclonal, Disease management, Review

摘要：

抗β-淀粉样蛋白（Aβ）单克隆抗体临床应用的成功，标志着阿尔茨海默病正式进入疾病修饰治疗时代。随着抗Aβ单克隆抗体逐步进入临床实践，临床关注重点已由规范启动治疗和淀粉样蛋白相关影像异常管理，进一步延伸至停药后长期管理。本文拟结合近年国内外Ⅲ期临床试验、真实世界研究以及国内临床实践，系统总结抗Aβ单克隆抗体的临床应用价值与局限性，并探讨疾病修饰治疗时代长期管理的发展方向。

关键词: 阿尔茨海默病, 淀粉样β肽类, 抗体，单克隆, 疾病管理, 综述

CLC Number: 

• R741